Cardiovascular Research

Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety.

Authors: Sumon Roy|||Robert A Kloner|||Fadi N Salloum|||Ion S Jovin

Affiliations: + Expand

Abstract

The coexistence of cardiovascular disease and erectile dysfunction is widespread, possibly owing to underlying endothelial dysfunction in both diseases. Millions of patients with cardiovascular disease are prescribed phosphodiesterase-5 (PDE5) inhibitors for the management of erectile dysfunction. Although the role of PDE5 inhibitors in erectile dysfunction therapy is well established, their effects on the cardiovascular system are unclear. Preclinical studies investigating the effect of PDE5 inhibitors on ischemia-reperfusion injury, pressure overload-induced hypertrophy, and chemotoxicity suggested a possible clinical role for each of these medications; however, attempts to translate these findings to the bedside have resulted in mixed outcomes. In this review, we explore the biologic preclinical effects of PDE5 inhibitors in mediating cardioprotection. We then examine clinical trials investigating PDE5 inhibition in patients with heart failure, coronary artery disease, and ventricular arrhythmias and discuss why the studies likely have yet to show positive results and efficacy with PDE5 inhibition despite no safety concerns.

---

Chemical List

Phosphodiesterase 5 Inhibitors|||Cyclic Nucleotide Phosphodiesterases, Type 5

---

Reference List

Garcia R. and Burkle J, New and future parenteral therapies for the management of lipid disorders. Arch Med Res, 2018. 49(8): p. 538–547.|||World Health Organization. Cardiovascular diseases. 2021. May 17, 2017 [accessed 2021 May 31, 2021]; Available from: https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).|||Writing Group M, et al., Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation, 2016. 133(4): p. e38–360.|||Fryar CD, Chen TC, and Li X, Prevalence of uncontrolled risk factors for cardiovascular disease: United States, 1999–2010. NCHS Data Brief, 2012(103): p. 1–8.|||Foster SA, et al., Erectile dysfunction with or without coexisting benign prostatic hyperplasia in the general US population: analysis of US National Health and Wellness Survey. Curr Med Res Opin, 2013. 29(12): p. 1709–17.|||Shaeer O. and Shaeer K, The Global Online Sexuality Survey (GOSS): the United States of America in 2011. Chapter I: erectile dysfunction among English-speakers. J Sex Med, 2012. 9(12): p. 3018–27.|||Goldstein I, et al., The serendipitous story of sildenafil: an unexpected oral therapy for erectile dysfunction. Sex Med Rev, 2019. 7(1): p. 115–128.|||Tzoumas N, et al., Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. Br J Pharmacol, 2019.|||Wallis RM, et al., Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol, 1999. 83(5A): p. 3C–12C.|||Corbin J, et al., Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr Med Res Opin, 2003. 19(8): p. 747–52.|||Reffelmann T. and Kloner RA, Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation, 2003. 108(2): p. 239–44.|||Salloum FN, et al., Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol, 2007. 42(2): p. 453–8.|||Inoue T, et al., cGMP upregulates nitric oxide synthase expression in vascular smooth muscle cells. Hypertension, 1995. 25(4 Pt 2): p. 711–4.|||Cai Z, Zhang J, and Li H, Two birds with one stone: regular use of PDE5 inhibitors for treating male patients with erectile dysfunction and cardiovascular diseases. Cardiovasc Drugs Ther, 2019. 33(1): p. 119–128.|||Loughney K, et al., Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3’,5’-cyclic nucleotide phosphodiesterase. Gene, 1998. 216(1): p. 139–47.|||Lu Z, et al., Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation, 2010. 121(13): p. 1474–83.|||Nagendran J, et al., Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation, 2007. 116(3): p. 238–48.|||Zhang M. and Kass DA, Phosphodiesterases and cardiac cGMP: evolving roles and controversies. Trends Pharmacol Sci, 2011. 32(6): p. 360–5.|||Gupta M, Kovar A, and Meibohm B, The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol, 2005. 45(9): p. 987–1003.|||Kukreja RC, Salloum FN, and Das A, Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J Am Coll Cardiol, 2012. 59(22): p. 1921–7.|||Nagayama T, et al., Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. J Mol Cell Cardiol, 2009. 46(4): p. 560–7.|||Blanton RM, et al., Protein kinase g ialpha inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc, 2012. 1(5): p. e003731.|||Das A, Xi L, and Kukreja RC, Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem, 2005. 280(13): p. 12944–55.|||Fisher PW, et al., Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation, 2005. 111(13): p. 1601–10.|||Carden DL and Granger DN, Pathophysiology of ischaemia-reperfusion injury. J Pathol, 2000. 190(3): p. 255–66.|||Das A, et al., Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol, 2004. 286(4): p. H1455–60.|||Salloum F, et al., Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res, 2003. 92(6): p. 595–7.|||Chen L, Shi D, and Guo M, The roles of PKC-delta and PKC-epsilon in myocardial ischemia/reperfusion injury. Pharmacol Res, 2021. 170: p. 105716.|||Ockaili R, et al., Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol, 2002. 283(3): p. H1263–9.|||Das S, et al., Cardioprotection with sildenafil, a selective inhibitor of cyclic 3’,5’monophosphate-specific phosphodiesterase 5. Drugs Exp Clin Res, 2002. 28(6): p. 213–9.|||Yellon DM and Downey JM, Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev, 2003. 83(4): p. 1113–51.|||Kukreja RC, et al., Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul Pharmacol, 2005. 42(5–6): p. 219–32.|||Oldenburg O, et al., Bradykinin induces mitochondrial ROS generation via NO, cGMP, PKG, and mitoKATP channel opening and leads to cardioprotection. Am J Physiol Heart Circ Physiol, 2004. 286(1): p. H468–76.|||Jankowski M, Broderick TL, and Gutkowska J, The role of oxytocin in cardiovascular protection. Front Psychol, 2020. 11: p. 2139.|||Paggio A, et al., Identification of an ATP-sensitive potassium channel in mitochondria. Nature, 2019. 572(7771): p. 609–613.|||Lukowski R, et al., cGMP and mitochondrial K(+) channels-compartmentalized but closely connected in cardioprotection. Br J Pharmacol, 2021.|||Elrod JW, Greer JJ, and Lefer DJ, Sildenafil-mediated acute cardioprotection is independent of the NO/cGMP pathway. Am J Physiol Heart Circ Physiol, 2007. 292(1): p. H342–7.|||Reffelmann T. and Kloner RA, Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res, 2003. 59(2): p. 441–9.|||Jones SP, et al., The NHLBI-sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR): a new paradigm for rigorous, accurate, and reproducible evaluation of putative infarct-sparing interventions in mice, rabbits, and pigs. Circ Res, 2015. 116(4): p. 572–86.|||Kukreja RC, et al., Administration of sildenafil at reperfusion fails to reduce infarct size: results from the CAESAR cardioprotection consortium (LB650). The FASEB Journal, 2014. 28: p. LB650.|||Takimoto E, et al., Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med, 2005. 11(2): p. 214–22.|||Salloum FN, et al., Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide. Circulation, 2009. 120(11 Suppl): p. S31–6.|||Gong W, et al., Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure. Br J Pharmacol, 2013. 170(7): p. 1396–409.|||Lipskaia L, et al., Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther, 2010. 10(1): p. 29–41.|||Frank K. and Kranias EG, Phospholamban and cardiac contractility. Ann Med, 2000. 32(8): p. 572–8.|||Nagayama T, et al., Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. J Am Coll Cardiol, 2009. 53(2): p. 207–15.|||El-Armouche A, et al., Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes. Biochem Biophys Res Commun, 2006. 346(3): p. 700–6.|||MacDonnell SM, et al., Calcineurin inhibition normalizes beta-adrenergic responsiveness in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol, 2007. 293(5): p. H3122–9.|||Pokreisz P, et al., Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation, 2009. 119(3): p. 408–16.|||Salloum FN, et al., Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol, 2008. 294(3): p. H1398–406.|||Hutchings DC, et al., Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart, 2018. 104(15): p. 1244–1250.|||Hutchings DC, et al., PDE5 inhibition suppresses ventricular arrhythmias by reducing SR Ca(2+) content. Circ Res, 2021.|||Cao JM, et al., Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation, 2000. 101(16): p. 1960–9.|||Lymperopoulos A, Rengo G, and Koch WJ, Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res, 2013. 113(6): p. 739–53.|||Lee DI, et al., PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation. Basic Res Cardiol, 2010. 105(3): p. 337–47.|||Cao JM, et al., Nerve sprouting and sudden cardiac death. Circ Res, 2000. 86(7): p. 816–21.|||Kreusser MM, et al., Differential expression of cardiac neurotrophic factors and sympathetic nerve ending abnormalities within the failing heart. J Mol Cell Cardiol, 2008. 44(2): p. 380–7.|||Shelton DL and Reichardt LF, Expression of the beta-nerve growth factor gene correlates with the density of sympathetic innervation in effector organs. Proc Natl Acad Sci U S A, 1984. 81(24): p. 7951–5.|||Kang CS, et al., Effect of ATP-sensitive potassium channel agonists on sympathetic hyperinnervation in postinfarcted rat hearts. Am J Physiol Heart Circ Physiol, 2009. 296(6): p. H1949–59.|||Lee TM, et al., Effect of sildenafil on ventricular arrhythmias in post-infarcted rat hearts. Eur J Pharmacol, 2012. 690(1–3): p. 124–32.|||Borlaug BA, et al., Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation, 2005. 112(17): p. 2642–9.|||Senzaki H, et al., Cardiac phosphodiesterase 5 (cGMP-specific) modulates betaadrenergic signaling in vivo and is down-regulated in heart failure. FASEB J, 2001. 15(10): p. 1718–26.|||Nagy O, et al., Sildenafil (Viagra) reduces arrhythmia severity during ischaemia 24 h after oral administration in dogs. Br J Pharmacol, 2004. 141(4): p. 549–51.|||Feenstra J, et al., Acute myocardial infarction associated with sildenafil. Lancet, 1998. 352(9132): p. 957–8.|||Herrmann HC, et al., Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med, 2000. 342(22): p. 1622–6.|||Andersson DP, et al., Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart, 2017. 103(16): p. 1264–1270.|||Andersson DP, et al., Association of phosphodiesterase-5 inhibitors versus alprostadil with survival in men with coronary artery disease. J Am Coll Cardiol, 2021. 77(12): p. 1535–1550.|||Thadani U, et al., The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol, 2002. 40(11): p. 2006–12.|||Patterson D, et al., The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Br J Clin Pharmacol, 2005. 60(5): p. 459–68.|||Vestergaard N, et al., Relationship between treatment of erectile dysfunction and future risk of cardiovascular disease: a nationwide cohort study. Eur J Prev Cardiol, 2017. 24(14): p. 1498–1505.|||Ali A, et al., The safety of preoperative vardenafil in patients undergoing coronary artery bypass graft surgery. J Cardiovasc Pharmacol, 2013. 62(1): p. 106–9.|||Fung E, et al., The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery. Chest, 2005. 128(4): p. 3065–73.|||Giannetta E, et al., Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med, 2014. 12: p. 185.|||Rosano GM, et al., Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol, 2005. 47(2): p. 214–20; discussion 220–2.|||Hackett G, et al., Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. World J Diabetes, 2017. 8(3): p. 104–111.|||Anderson SG, et al., Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart, 2016. 102(21): p. 1750–1756.|||Gazzaruso C, et al., Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol, 2008. 51(21): p. 2040–4.|||Guazzi M, et al., Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol, 2007. 50(22): p. 2136–44.|||Guazzi M, et al., PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Fail, 2011. 4(1): p. 8–17.|||Lewis GD, et al., Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation, 2007. 116(14): p. 1555–62.|||Amin A, et al., Is chronic sildenafil therapy safe and clinically beneficial in patients with systolic heart failure? Congest Heart Fail, 2013. 19(2): p. 99–103.|||Guazzi M, et al., Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation, 2011. 124(2): p. 164–74.|||Redfield MM, et al., Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA, 2013. 309(12): p. 1268–77.|||Guay CA, et al., Pulmonary hypertension-targeted therapies in heart failure: a systematic review and meta-analysis. PLoS One, 2018. 13(10): p. e0204610.|||Zhuang XD, et al., PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol, 2014. 172(3): p. 581–7.|||Shah PK, Sildenafil in the treatment of erectile dysfunction. N Engl J Med, 1998. 339(10): p. 699; author reply 701–2.|||Rasmussen JG, Toft E, and Frobert O, Ventricular tachycardia after administration of sildenafil citrate: a case report. J Med Case Rep, 2007. 1: p. 65.|||Alpaslan M, et al., Sildenafil citrate does not affect QT intervals and QT dispersion: an important observation for drug safety. Ann Noninvasive Electrocardiol, 2003. 8(1): p. 14–7.|||Beasley CM Jr., et al., The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval. J Am Coll Cardiol, 2005. 46(4): p. 678–87.|||Morganroth J, et al., Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol, 2004. 93(11): p. 1378–83, A6.|||Varma A, Shah KB, and Hess ML, Phosphodiesterase inhibitors, congestive heart failure, and sudden death: time for re-evaluation. Congest Heart Fail, 2012. 18(4): p. 229–33.|||Ravichandran AK, et al., Sildenafil in left ventricular assist device is safe and well-tolerated. ASAIO J, 2018. 64(2): p. 280–281.|||Gulati G, et al., Preimplant phosphodiesterase-5 inhibitor use is asssociated with higher rates of severe early right heart failure after left ventricular assist device implantation. Circ Heart Fail, 2019. 12(6): p. e005537.|||Roberts KL, et al., Evaluation of clinical outcomes with phosphodiesterase-5 inhibitor therapy for right ventricular dysfunction after left ventricular assist device implantation. ASAIO J, 2019. 65(3): p. 264–269.|||Hamdan R, et al., Prevention of right heart failure after left ventricular assist device implantation by phosphodiesterase 5 inhibitor. Artif Organs, 2014. 38(11): p. 963–7.|||Baker WL, Radojevic J, and Gluck JA, Systematic review of phosphodiesterase-5 inhibitor use in right ventricular failure following left ventricular assist device implantation. Artif Organs, 2016. 40(2): p. 123–8.|||Corbin JD, et al., High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun, 2005. 334(3): p. 930–8.|||Montani D, et al., Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther, 2009. 26(9): p. 813–25.|||Rubin LJ, et al., Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest, 2011. 140(5): p. 1274–1283.|||Pepke-Zaba J, et al., Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest, 2008. 133(1): p. 183–9.|||Oudiz RJ, et al., Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. J Am Coll Cardiol, 2012. 60(8): p. 768–74.|||Pepke-Zaba J, et al., Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin, 2009. 25(10): p. 2479–85.|||Galie N, et al., Tadalafil therapy for pulmonary arterial hypertension. Circulation, 2009. 119(22): p. 2894–903.|||Kloner RA, et al., Cardiovascular safety of phosphodiesterase type 5 inhibitors after nearly 2 decades on the market. Sex Med Rev, 2018. 6(4): p. 583–594.